MASH Diagnostics Market to Reach US$ 7.72 billion by 2035, Powered by AI Imaging, Biomarkers and Early Disease Detection Technologies

DataM Intelligence has published its latest research report, "MASH Diagnostics Market Size 2026-2035." The report provides comprehensive insights into market trends, regional opportunities, competitive dynamics, CAGR forecasts, and the revenue performance of leading companies. It also examines key growth drivers, emerging investment opportunities, and strategic developments influencing the industry, the report delivers a detailed assessment of market value, volume, future growth potential, and the evolving global MASH Diagnostics Market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/mash-diagnostics-market?kb

United States: Recent Industry Developments

✅ May 2026: Prometheus Laboratories presented translational data at DDW 2026 supporting development of a next-generation blood-based non-invasive diagnostic test for identifying treatment-eligible MASH patients.

✅ May 2026: Hepta reported clinical data showing its blood test outperformed FIB-4, ELF, and FibroScan in identifying treatment-eligible MASH patients with significant fibrosis.

✅ January 2026: HistoIndex expanded partnerships with leading U.S. medical centers to advance AI-powered biopsy analysis and quantitative fibrosis assessment for MASH diagnostics.

✅ December 2025: The U.S. FDA qualified AIM-NASH, the first AI-based drug development tool for standardized histologic assessment in MASH clinical trials, supporting faster and more consistent diagnostics.

Unlock growth potential in the MASH Diagnostics Market with the right insights, partners, and strategic opportunities:- https://www.datamintelligence.com/partner-identification-enquiry/mash-diagnostics-market?kb

Top List of Key Players 2026:

Echosens, Siemens Healthineers AG, Perspectum Limited, Nordic Bioscience, BioPredictive, Rubió Metabolomics, PathAI, Inc., Histoindex Pte Ltd., F. Hoffmann-La Roche Ltd., GE HealthCare, Koninklijke Philips N.V.

Growth Forecast Projected 2026:

The Global MASH Diagnostics Market is expected to witness strong growth throughout the forecast period from 2026 to 2035. Following steady market expansion in 2025, increasing investments, product innovations, regulatory advancements, and strategic initiatives by leading companies are anticipated to accelerate market growth over the forecast period.

Key Developments 2026:

In June 2026, Roche launched the Liver Disease Panel on its navify Algorithm Suite, integrating AI-powered algorithms and biomarkers such as Elecsys PRO-C3 to improve non-invasive diagnosis and fibrosis assessment for MASLD and MASH patients.

In June 2026, Labcorp expanded its biomarker portfolio for MASLD/MASH research, highlighting advanced diagnostic assays including GENFIT's NIS2+ and NIS4 blood-based biomarkers and Nordic Bioscience's PRO-C3 to support clinical trials and patient stratification.

In March 2026, Labcorp introduced expanded genotyping assays for detecting genetic variants associated with MASLD and MASH, strengthening precision diagnostics and biomarker-driven clinical development.

In January 2026, GENFIT continued expanding the clinical adoption of its NIS2+ blood-based diagnostic technology for identifying at-risk fibrotic MASH patients, supporting pharmaceutical clinical trials and non-invasive patient selection through collaborations with diagnostic partners.

How Our Market Research Process Works:

The global MASH Diagnostics Market research report is built on a robust combination of primary research and validated secondary research. It delivers strategic analysis of regulatory developments, competitive positioning, evolving market dynamics, and historical industry performance to support informed business decisions. The study further examines technological innovations, product advancements, and trends across adjacent healthcare sectors, while evaluating growth opportunities, investment potential, market risks, and key challenges shaping the future of the global MASH Diagnostics Market.

Recent Mergers & Acquisitions (M & A) 2026:

• May 2026: Danaher shareholders approved the acquisition of Masimo Corporation, strengthening Danaher's diagnostics and patient monitoring portfolio.

• June 2026: Photocure ASA acquired Vesica Health Inc. to expand its molecular diagnostics portfolio for bladder cancer detection.

Request Industry Strategic Market Customization: https://datamintelligence.com/customize/mash-diagnostics-market?kb

Japan: Recent Industry Developments

✅ May 2026: FUJIFILM Healthcare continued expanding AI-enabled digital pathology solutions supporting liver disease assessment and precision diagnostic workflows for MASH research.

✅ March 2026: Sysmex Corporation strengthened collaborations in AI-driven pathology and biomarker technologies to improve non-invasive liver disease diagnostics and clinical decision support.

✅ February 2026: Eiken Chemical Co., Ltd. advanced molecular diagnostic capabilities and biomarker research supporting early detection of metabolic liver diseases, including MASH.

✅ January 2026: Fujirebio Holdings, Inc. expanded development of blood-based biomarker technologies aimed at improving non-invasive liver disease diagnosis and monitoring for MASH patients.

Major Focused Key Segmentations 2026:

By Diagnostic Workflow Stage: Initial Screening Methods, Liver Function Tests, ALT Testing, AST Testing, Platelet Count, Ultrasound Screening, Primary Care Risk Screening, Diabetes Screening Based Liver Assessment, Obesity Risk Based Screening, Metabolic Syndrome Screening, MASH Confirmation Methods, Liver Biopsy, MRI PDFF, Magnetic Resonance Elastography, FibroScan Confirmation, Histopathology Confirmation, Biomarker Based Confirmation, Combined Imaging and Biomarker Confirmation, Fibrosis Staging Methods, FIB 4 Score, NAFLD Fibrosis Score, Enhanced Liver Fibrosis Test, FibroScan, Magnetic Resonance Elastography, APRI Score, Liver Biopsy Staging, Histological Fibrosis Grading, Treatment Monitoring Methods, ALT Monitoring, AST Monitoring, FibroScan Follow Up, MRI PDFF Follow Up, Biomarker Monitoring, Repeat Liver Function Testing, Disease Regression Tracking, Disease Progression Surveillance Methods, Fibrosis Monitoring, Cirrhosis Risk Tracking, Repeat Imaging Assessment, Liver Function Monitoring, Hepatology Follow Up, Longitudinal Biomarker Tracking, Emerging Diagnostic Technologies, AI Based Risk Scoring, AI Imaging Interpretation, Multiomics Diagnostics, Genomic Risk Profiling, RNA Biomarkers, Digital Pathology, Predictive Analytics Platforms, Companion Diagnostics

By Diagnostic Method: Imaging Diagnostics, Ultrasound, FibroScan, MRI PDFF, Magnetic Resonance Elastography, CT Imaging, Contrast Enhanced Imaging, Blood Based Diagnostics, Liver Enzyme Tests, ALT and AST, Enhanced Liver Fibrosis Test, FIB 4 Index, NAFLD Fibrosis Score, Cytokeratin 18 Biomarkers, Inflammatory Biomarkers, Lipid Profile Markers, Others, Histopathology Diagnostics, Liver Biopsy, Histological Grading, Fibrosis Scoring, Tissue Based Biomarker Analysis, Molecular Diagnostics, RNA Biomarkers, DNA Biomarkers, Genomic Panels, Multiomics Diagnostics, Precision Biomarker Panels, Others, AI Enabled Diagnostics, AI Imaging Algorithms, Automated Fibrosis Scoring, Predictive Risk Models, Digital Liver Pathology

By Diagnostic Purpose: Screening Diagnostics, Disease Confirmation Diagnostics, Fibrosis Staging Diagnostics, Therapy Eligibility Diagnostics, Companion Diagnostics, Treatment Monitoring Diagnostics, Disease Surveillance Diagnostics, Progression Tracking Diagnostics

By Disease Severity: MASLD, Early MASH, Mild Fibrosis, Moderate Fibrosis, Advanced Fibrosis, Severe Fibrosis, Cirrhosis Stage, High Risk Progression Population

By End-User: Hospitals, Hepatology Clinics, Gastroenterology Clinics, Diagnostic Laboratories, Imaging Centers, Specialty Liver Centers, Academic Research Centers, Ambulatory Diagnostic Centers

Regional Growth Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

We Provide Benefits of the Report:

Chapter 1: Establishes the report framework by defining the market scope and analyzing key segments across regions, product categories, and applications. It provides a strategic overview of current market size, growth opportunities, and the future outlook shaping industry expansion.

Chapter 2: Highlights the most significant market insights, identifying key trends, emerging opportunities, and critical factors influencing the industry's future direction.

Chapter 3: Delivers an in-depth competitive landscape analysis, covering market positioning, revenue contribution, strategic developments, and major mergers and acquisitions influencing market competitiveness.

Chapter 4: Profiles leading industry players with insights into financial performance, product offerings, business strategies, profitability indicators, and key achievements driving their market presence.

Chapters 5 & 6: Provide comprehensive regional and country-level revenue analysis, highlighting market size, growth factors, investment opportunities, and expansion potential across key global markets.

Chapter 7: Examines the market based on product segmentation, identifying high-growth segments, emerging demand areas, and strategic opportunities for industry participants.

Chapter 8: Analyzes application-based market segments, evaluating end-user demand, industry adoption patterns, and downstream opportunities with significant growth potential.

Chapter 9: Provides a detailed assessment of the industry supply chain, mapping upstream suppliers, downstream activities, and value creation opportunities across the market ecosystem.

Chapter 10: Concludes the report with a strategic summary of key findings, actionable insights, and critical takeaways designed to support informed decisions by executives and stakeholders.

Buy Full 360° Market Report: https://www.datamintelligence.com/buy-now-page?report=mash-diagnostics-market?kb

FAQ

Q1: What is the current size of the MASH Diagnostics Market Market?

A: The MASH Diagnostics Market reached a valuation of US$ 1.41 billion in 2025 and is projected to grow to US$ 7.72 billion by 2035

Q2: How rapidly will the Market expand?

A: The MASH Diagnostics Market is expected to expand at a CAGR of 23.94% from 2026 to 2035

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us:

Sai Kiran
Business Development Manager
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.